Pneumatocele during sorafenib therapy: first report of an unusual complication

Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangro, Paloma, Bilbao, Idoia, Fernández-Ros, Nerea, Iñarrairaegui, Mercedes, Zulueta, Javier, Bilbao, JI, Sangro, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/
https://www.ncbi.nlm.nih.gov/pubmed/29464101
http://dx.doi.org/10.18632/oncotarget.23599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/
https://www.ncbi.nlm.nih.gov/pubmed/29464101
http://dx.doi.org/10.18632/oncotarget.23599

Ejemplares similares